Literature DB >> 25251052

New initiatives for pharmacovigilance in South Korea: introducing the Korea Institute of Drug Safety and Risk Management (KIDS).

Ju-Young Shin1, Sun-Young Jung, So-Hyeon Ahn, Shin Haeng Lee, Su-Jin Kim, Jong-Mi Seong, Soo-Youn Chung, Byung-Joo Park.   

Abstract

PURPOSE: Pharmacovigilance plays a vital role in ensuring that patients receive appropriate medical products that are safe and effective. This paper aims to describe the history of pharmacovigilance in Korea and introduce the establishment and goal of the KIDS.
METHODS: In Korea, the adverse drug reactions (ADR) reporting system was launched in 1988 by the Korea Ministry of Food and Drug Safety (MFDS) and spontaneous ADR reports have been collected from health care professionals and the general public. Although the ADR reporting system has begun, the reporting rate was very low in the first 10 years, and safety actions were done passively in response to the US Food and Drug Administration (FDA) or European Medicines Agency (EMA)'s safety alert and communications.
RESULTS: Therefore, the Korea Institute of Drug Safety and Risk Management (KIDS) was established in April 2012 as a new initiative for pharmacovigilance.
CONCLUSIONS: The KIDS will continue to contribute to the improvement of Korean pharmacovigilance by collecting, managing, and analyzing consumer-centered drug safety information.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Korea Institute of Drug Safety and Risk Management; adverse drug reactions; drug utilization review; pharmacoepidemiology; pharmacovigilance

Mesh:

Year:  2014        PMID: 25251052     DOI: 10.1002/pds.3715

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  9 in total

1.  Effects of a Safety Letter on Metoclopramide Use in Korea: An Interrupted Time-Series Analysis.

Authors:  Hyungtae Kim; Hae Sun Suh
Journal:  Risk Manag Healthc Policy       Date:  2020-08-25

2.  Effect of providing drug utilization review information on tricyclic antidepressant prescription in the elderly.

Authors:  Mi-Ju Park; Mi-Hee Kim; Sun Mi Shin; Soo Youn Chung
Journal:  J Med Syst       Date:  2018-09-13       Impact factor: 4.460

3.  Differential completeness of spontaneous adverse event reports among hospitals/clinics, pharmacies, consumers, and pharmaceutical companies in South Korea.

Authors:  In-Sun Oh; Yeon-Hee Baek; Hye-Jun Kim; Mose Lee; Ju-Young Shin
Journal:  PLoS One       Date:  2019-02-14       Impact factor: 3.240

4.  Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007-2016.

Authors:  Dongmun Ha; So-Ra Choi; Yongmin Kwon; Han-Heui Park; Ju-Young Shin
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

5.  Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis.

Authors:  Joo Hee Kim; Ji Young Park; Seung Hun Jang; Jwa Kyung Kim; Young Rim Song; Hyung Seok Lee; Sung Gyun Kim
Journal:  Allergy Asthma Immunol Res       Date:  2021-05       Impact factor: 5.764

6.  Detecting early safety signals of infliximab using machine learning algorithms in the Korea adverse event reporting system.

Authors:  Jeong-Eun Lee; Ju Hwan Kim; Ji-Hwan Bae; Inmyung Song; Ju-Young Shin
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

Review 7.  Past, present, and future of pharmacovigilance in Korea.

Authors:  Dong Yoon Kang; Kyung-Min Ahn; Hye-Ryun Kang; Sang-Heon Cho
Journal:  Asia Pac Allergy       Date:  2017-07-19

8.  Development of an adverse events reporting form for Korean folk medicine.

Authors:  Jeong Hwan Park; Sun-Mi Choi; Sujeong Moon; Sungha Kim; Boyoung Kim; Min-Kyeoung Kim; Sanghun Lee
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-08-08       Impact factor: 2.890

9.  Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database.

Authors:  Hyeong-Geun Jo; Kyeoul Jeong; Ji-Young Ryu; Soyun Park; Yun-Seok Choi; Won-Gun Kwack; Yeo-Jin Choi; Eun-Kyoung Chung
Journal:  J Pers Med       Date:  2021-12-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.